Ethopropazine

Summary

Ethopropazine (CHEMBL1206) is an approved small-molecule muscarinic antagonist (ATC N04AA05) targeting CHRM1 and CHRM2; indicated across 1 condition including parkinson disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N04AA05
• Targets: 2 (CHRM1, CHRM2)
• Indications: 1 condition
• Chemistry: 312.5 Da · C19H24N2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1206
Name	Ethopropazine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3290
ChEBI	CHEBI:313639
ATC	N04AA05
Molecular formula	C19H24N2S
Molecular weight	312.5
InChIKey	CDOZDBSBBXSXLB-UHFFFAOYSA-N

SMILES: CCN(CC)C(C)CN1C2=CC=CC=C2SC3=CC=CC=C31

IUPAC name: N,N-diethyl-1-phenothiazin-10-ylpropan-2-amine

ChEBI definition: A member of the class of phenothiazines that is phenothiazine in which the hydrogen attached to the nitrogen is substituted by a 2-(diethylamino)propyl group. An antimuscarinic, it is used as the hydrochloride for the symptomatic treatment of Parkinson’s disease.

Pharmacological roles (ChEBI): muscarinic antagonist, antiparkinson drug, histamine antagonist, adrenergic antagonist, antidyskinesia agent.

Also known as: Profenamina, Profenamine, RP-3356, SC-2538, W-483, SID11112467, SID90341779, Ethopropazine, ethopropazine, ETHOPROPAZINE, PROFENAMINE, profenamine

Parent form; salt/anhydrous children: CHEMBL1200970

Patent coverage: 5,219 distinct patent families (15,984 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 15,966 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CHRM1	M1 receptor	Antagonist	8.51	0.2%	P11229
CHRM2	M2 receptor	Antagonist	8.14	0%	P08172

Broader ChEMBL bioactivity targets: 26 (assay-derived). Sample: Lysine-specific demethylase 4E, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Alpha-2A adrenergic receptor, Cholinesterase, Amine oxidase [flavin-containing] A, D(1A) dopamine receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Acetylcholinesterase.

Bioactivity

ChEMBL activities: 25 potent at pChembl ≥ 5 of 34 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
BCHE	7.7	Ki	20	nM	CHEMBL_ACT_137215
BCHE	7.7	Ki	20	nM	CHEMBL_ACT_24829954
CHRM1	7.44	AC50	36.6	nM	CHEMBL_ACT_25210341
CHRM2	7.34	AC50	46.1	nM	CHEMBL_ACT_25195886
CYP2D6	6.8	Potency	158.5	nM	CHEMBL_ACT_4990260
CYP2D6	6.8	AC50	158.5	nM	CHEMBL_ACT_6041744
BCHE	6.68	IC50	210	nM	CHEMBL_ACT_19289722
ACHE	6.58	IC50	260	nM	CHEMBL_ACT_15133454
ACHE	6.58	IC50	260	nM	CHEMBL_ACT_6217801
BCHE	6.52	IC50	300	nM	CHEMBL_ACT_15133450
ACHE	6.52	IC50	300	nM	CHEMBL_ACT_6217819
ACHE	6.52	IC50	300	nM	CHEMBL_ACT_6217829
CYP1A2	6.3	AC50	501.2	nM	CHEMBL_ACT_6016078
P81908	6.14	IC50	720	nM	CHEMBL_ACT_6217879
DRD3	5.63	AC50	2315	nM	CHEMBL_ACT_25194668
OPRM1	5.54	AC50	2901	nM	CHEMBL_ACT_25158325
ADRA1A	5.48	AC50	3326	nM	CHEMBL_ACT_25218978
HIF1A	5.4	Potency	3981	nM	CHEMBL_ACT_4125661
HIF1A	5.4	Potency	3981	nM	CHEMBL_ACT_4519870
HTR1A	5.32	AC50	4820	nM	CHEMBL_ACT_25165174
DRD1	5.27	AC50	5421	nM	CHEMBL_ACT_25115360
ADRA2A	5.17	AC50	6838	nM	CHEMBL_ACT_25156579
KDM4E	5.1	Potency	7943	nM	CHEMBL_ACT_3720032
KCNH2	5	AC50	10000	nM	CHEMBL_ACT_25117908
ALDH1A1	5	Potency	10000	nM	CHEMBL_ACT_4153692

Target pathways

Aggregated over 2 target gene(s): CHRM1, CHRM2.

Top Reactome pathways

13 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	2	CHRM1, CHRM2
Signaling by GPCR	2	CHRM1, CHRM2
Class A/1 (Rhodopsin-like receptors)	2	CHRM1, CHRM2
Amine ligand-binding receptors	2	CHRM1, CHRM2
GPCR downstream signalling	2	CHRM1, CHRM2
Muscarinic acetylcholine receptors	2	CHRM1, CHRM2
GPCR ligand binding	2	CHRM1, CHRM2
Membrane Trafficking	1	CHRM2
G alpha (q) signalling events	1	CHRM1
G alpha (i) signalling events	1	CHRM2
Vesicle-mediated transport	1	CHRM2
Cargo recognition for clathrin-mediated endocytosis	1	CHRM2
Clathrin-mediated endocytosis	1	CHRM2

Dominant GO biological processes

GO term	Targets
signal transduction	2
G protein-coupled receptor signaling pathway	2
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	2
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	2
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	2
G protein-coupled acetylcholine receptor signaling pathway	2
chemical synaptic transmission	2
nervous system development	2
phospholipase C-activating G protein-coupled receptor signaling pathway	1
neuromuscular synaptic transmission	1
regulation of locomotion	1
positive regulation of monoatomic ion transport	1
saliva secretion	1
cognition	1
regulation of postsynaptic membrane potential	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Parkinson disease	4	MONDO:0005180	MONDO:0005180

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

537 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
Afatinib	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2
chenodiol	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2
LINAGLIPTIN	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2
Mavorixafor	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2
PIMAVANSERIN	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2
VORAPAXAR	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2
ACETYLCHOLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
ACLIDINIUM BROMIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
AMBENONIUM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
AMDINOCILLIN PIVOXIL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
AMIODARONE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
AMODIAQUINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
AMOXAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
ANISOTROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
ATROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
AZATADINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
AZELASTINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
BENPERIDOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
BENZTROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
BENZYDAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
BETHANECHOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
BIPERIDEN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
BROMODIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
BROMPHENIRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CABOZANTINIB	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CARBACHOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CARBAMOYLCHOLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CARBETAPENTANE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CARIPRAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CASPOFUNGIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CEVIMELINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CHLORMADINONE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CHLOROQUINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CHLORPROTHIXENE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CINNARIZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CITALOPRAM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CLEMASTINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CLIDINIUM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CLOMIPHENE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CLOZAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
COBIMETINIB	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CYCLIZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CYCLOBENZAPRINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CYCLOFENIL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CYCLOPENTOLATE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
DARIFENACIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
DEQUALINIUM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
DESIPRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2
DESLORATADINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2